Missing the earnings estimate by -36.0% and reporting unchanged revenue could negatively impact investor sentiment towards Allarity Therapeutics. Historically, earnings misses have led to declines in stock prices as they may reflect operational challenges or lower-than-expected growth. Given the company's previous quarter performance where a beat in EPS estimates led to a stock price increase, this miss could reverse some of those gains.